Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Forum Dermatologicum
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

Vol 8, No 3 (2022)
Research paper
Published online: 2022-09-30
Add to basket: 49.00 PLN
Get Citation

Assessment of the effectiveness of Solverx® products — Atopic Forte cleansing emulsion and Atopic Forte body lotion in relieving the symptoms of atopic dermatitis

Irmina Olejniczak-Staruch1, Joanna Narbutt1, Magdalena Ciążyńska1, Małgorzata Szulc1, Aleksandra Lesiak1
DOI: 10.5603/FD.2022.0007
·
Forum Dermatologicum 2022;8(3):131-138.
Affiliations
  1. Dermoklinika Centrum Medyczne s.c. M. Kierstan, J. Narbutt, A. Lesiak

paid access

Vol 8, No 3 (2022)
ORIGINAL ARTICLES
Published online: 2022-09-30

Abstract

Introduction: Atopic dermatitis (AD) is a chronic dermatosis characterized by the presence of typical erythematous lesions with lichenification, dry skin and accompanying itching. The mainstay of AD treatment is emollient therapy and avoidance of factors that aggravate skin lesions. The aim of the study was to evaluate the effectiveness of Atopic Forte Cleansing Emulsion and Solverx® Atopic Forte Body Lotion in relieving AD symptoms. Material and methods: The study group consisted of 50 patients (25 adults and 25 children) suffering from mild or moderate AD. At the beginning and after 2 weeks of use of the study products, the following measurements were made: transepidermal water loss (TEWL), sebum density and skin pH, the severity of skin lesions was assessed (IGA, Investigators’ Global Assessment) scale. Patients completed questionnaires regarding the patient’s preferences and satisfaction with the use of the products. Results: The mean TEWL level after 2 weeks of using the products significantly decreased (from 21.29 ± 7.02 to 13.93 ± 4.90 g/ h/m2, p = 0.0023), while the sebum density increased significantly (from 1.28 ± 1.05 to 2.48 ± 0.94 μg/cm2, p < 0.0001). The severity of skin lesions improved significantly (IGA: 1.70 ± 0.72 and 0.92 ± 0.67, p <0.0001, respectively). Patients in the questionnaires reported a reduction in symptoms (dryness, itching), restoration of skin comfort, with high tolerance of use. Conclusions: The Solverx® brand products — Atopic Forte Wash Emulsion and Atopic Forte Body Lotion reduce the severity of lesions and relieve symptoms in patients with mild and moderate atopic dermatitis.

Abstract

Introduction: Atopic dermatitis (AD) is a chronic dermatosis characterized by the presence of typical erythematous lesions with lichenification, dry skin and accompanying itching. The mainstay of AD treatment is emollient therapy and avoidance of factors that aggravate skin lesions. The aim of the study was to evaluate the effectiveness of Atopic Forte Cleansing Emulsion and Solverx® Atopic Forte Body Lotion in relieving AD symptoms. Material and methods: The study group consisted of 50 patients (25 adults and 25 children) suffering from mild or moderate AD. At the beginning and after 2 weeks of use of the study products, the following measurements were made: transepidermal water loss (TEWL), sebum density and skin pH, the severity of skin lesions was assessed (IGA, Investigators’ Global Assessment) scale. Patients completed questionnaires regarding the patient’s preferences and satisfaction with the use of the products. Results: The mean TEWL level after 2 weeks of using the products significantly decreased (from 21.29 ± 7.02 to 13.93 ± 4.90 g/ h/m2, p = 0.0023), while the sebum density increased significantly (from 1.28 ± 1.05 to 2.48 ± 0.94 μg/cm2, p < 0.0001). The severity of skin lesions improved significantly (IGA: 1.70 ± 0.72 and 0.92 ± 0.67, p <0.0001, respectively). Patients in the questionnaires reported a reduction in symptoms (dryness, itching), restoration of skin comfort, with high tolerance of use. Conclusions: The Solverx® brand products — Atopic Forte Wash Emulsion and Atopic Forte Body Lotion reduce the severity of lesions and relieve symptoms in patients with mild and moderate atopic dermatitis.

Full Text:

Add to basket: 49.00 PLN
Get Citation

Keywords

emolients, atopic dermatitis, TEWL

About this article
Title

Assessment of the effectiveness of Solverx® products — Atopic Forte cleansing emulsion and Atopic Forte body lotion in relieving the symptoms of atopic dermatitis

Journal

Forum Dermatologicum

Issue

Vol 8, No 3 (2022)

Article type

Research paper

Pages

131-138

Published online

2022-09-30

Page views

998

Article views/downloads

18

DOI

10.5603/FD.2022.0007

Bibliographic record

Forum Dermatologicum 2022;8(3):131-138.

Keywords

emolients
atopic dermatitis
TEWL

Authors

Irmina Olejniczak-Staruch
Joanna Narbutt
Magdalena Ciążyńska
Małgorzata Szulc
Aleksandra Lesiak

References (12)
  1. Leung AKC, Hon KLE, Robson WmL. Atopic dermatitis. Adv Pediatr. 2007; 54: 241–273.
    CrossRefPubMed
  2. Leung TNH, Hon KL, Leung TNH, et al. Eczema therapeutics in children: what do the clinical trials say? Hong Kong Med J. 2015; 21(3): 251–260.
    CrossRefPubMed
  3. van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017; 6(2): CD007770.
    CrossRefPubMed
  4. Giam YC, Hebert AA, Dizon MV, et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016; 6(2): 120–128.
    CrossRefPubMed
  5. Hon KL, Leung AKC, Barankin B. Barrier repair therapy in atopic dermatitis: an overview. Am J Clin Dermatol. 2013; 14(5): 389–399.
    CrossRefPubMed
  6. Mengeaud V, Phulpin C, Bacquey A, et al. An innovative oat-based sterile emollient cream in the maintenance therapy of childhood atopic dermatitis. Pediatr Dermatol. 2015; 32(2): 208–215.
    CrossRefPubMed
  7. Åkerström U, Reitamo S, Langeland T, et al. Comparison of Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse: A Randomized Double-blind Controlled Multicentre Clinical Trial. Acta Derm Venereol. 2015; 95(5): 587–592.
    CrossRefPubMed
  8. Breternitz M, Kowatzki D, Langenauer M, et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008; 21(1): 39–45.
    CrossRefPubMed
  9. Nowicki RJ, Trzeciak M, Kaczmarski M, et al. Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part I. Prophylaxis, topical treatment and phototherapy. Postepy Dermatol Alergol. 2020; 37(1): 1–10.
    CrossRefPubMed
  10. Hon KL, Tsang YC, Pong NH, et al. Patient acceptability, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema. Hong Kong Med J. 2015; 21(5): 417–425.
    CrossRefPubMed
  11. Narbutt J, Lesiak A. I-modulia® w badaniach klinicznych – zastosowanie emolientów u chorych na atopowe zapalenie skóry. Forum Dermatologicum. 2016; 2(4): 139–143.
  12. Welz-Kubiak K, Reich A. Znaczenie emolientów w codziennej pielęgnacji skóry. Forum Dermatologicum. 2016; 2(1): 20–23.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl